Document:

THIS
      NOTE
      HAS NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND
      EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE OR UNDER THE
      SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THE SECURITIES ARE RESTRICTED
      AND MAY NOT BE OFFERED, RESOLD, PLEDGED OR TRANSFERRED EXCEPT AS PERMITTED
      UNDER
      THE ACT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR AN EXEMPTION FROM
      SUCH REGISTRATION REQUIREMENTS.

     

    
      	No. __  	
              $_________
                Principal
                Amount

            

    

     

    Original
      Issuance: September ___, 2006

    

    BioMetrx,
      Inc.

    

    10%
      NOTE DUE March 15, 2007

     

    THIS
      NOTE
      is issued by BioMetrx,
      Inc.,
      a
      Delaware corporation (the “Company”),
      and is
      part of an issue of an aggregate of up to $400,000 principal amount of Notes
      due
      March 15, 2007 (the “Notes”).

    

    FOR
      VALUE
      RECEIVED, the Company promises to pay to ______________,
      or
      permitted assigns (the “Holder”),
      the
      principal sum of _________ and
      00/100 (US $_________) Dollars
      on March
      15, 2007 (the “Maturity
      Date”)
      and to
      pay simple interest on the principal sum outstanding at the rate of 10% per
      annum. Accrual of interest shall commence on the date of initial issuance set
      forth the above (“Original
      Issuance”)
      and
      continue daily on the basis of a 360 day year until payment in full of the
      principal sum has been made or duly provided for. If the Maturity Date is not
      a
      business day in the State of New York, then such payment shall be made on the
      next succeeding business day. Subject to the provisions of Section 3 below,
      principal and accrued interest on this Note are payable in cash on the Maturity
      Date, at the address last appearing on the Note Register (as defined below)
      of
      the Company as designated in writing by the Holder from time to time. The
      Company will pay the principal of and any accrued but unpaid interest due upon
      this Note on the Maturity Date, less any amounts required by law to be deducted,
      to the registered holder of this Note as of the fifth day prior to the Maturity
      Date and addressed to such holder at the last address appearing on the Note
      register maintained by or on behalf of the Company (the “Note
      Register”).
      The
      forwarding of such check representing immediately available funds shall
      constitute a payment of principal and interest hereunder and shall satisfy
      and
      discharge the liability for principal and interest on this Note to the extent
      of
      the sum represented by such check, plus any amounts so deducted.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    This
      Note
      is subject to the following additional provisions:

    

    1.    Withholding
      and Issuance Taxes.
      The
      Company shall be entitled to withhold from all payments of principal of, and
      interest on, this Note any amounts required to be withheld under the applicable
      provisions of the United States income tax laws or other applicable laws at
      the
      time of such payments, and Holder shall execute and deliver all required
      documentation in connection therewith. 

    

    2.    Transfer
      of Note.
      This
      Note has been issued subject to investment representations of the original
      purchaser hereof and may be transferred or exchanged only in compliance with
      the
      Securities Act of 1933, as amended (the “Securities
      Act”),
      and
      other applicable state and foreign securities laws. The Holder shall deliver
      written notice to the Company of any proposed transfer of this Note. In the
      event of any proposed transfer of this Note, the Company may require, prior
      to
      issuance of a new Note in the name of such other person, that it receive
      reasonable transfer documentation including legal opinions that the issuance
      of
      the Note in such other name does not and will not cause a violation of the
      Securities Act or any applicable state or foreign securities laws. Prior to
      due
      presentment for transfer of this Note, the Company and any agent of the Company
      may treat the person in whose name this Note is duly registered on the Company’s
      Note Register as the owner hereof for the purpose of receiving payment as herein
      provided and for all other purposes, whether or not this Note be overdue, and
      neither the Company nor any such agent shall be affected by notice to the
      contrary. This Note has been executed and delivered pursuant to the Securities
      Purchase Agreement dated as of September 15, 2006 between the Company and the
      original Holder (the “Purchase
      Agreement”),
      and is
      subject to the terms and conditions of the Purchase Agreement, which are, by
      this reference, incorporated herein and made a part hereof. Capitalized terms
      used and not otherwise defined herein shall have the meanings set forth for
      such
      terms in the Purchase Agreement.

    

    3.    Notices.
      In case
      at any time:

    

    (a)    the
      Company shall declare any dividend upon its members payable in cash or stock
      or
      make any other pro rata distribution to the holders of its Common Stock; or
      

    

    (b)    the
      Company shall offer for subscription pro rata
      to the
      holders of its equity any additional equity interest of any class or other
      rights; or 

    

    (c)    there
      shall be any capital reorganization or reclassification of the equity of the
      Company, or a consolidation or merger of the Company with or into, or a sale
      of
      all or substantially all its assets to, another entity or entities; or

    

    (d)    there
      shall be a voluntary or involuntary dissolution, liquidation or winding up
      of
      the Company; then, in any one or more of said cases, the Company shall give,
      by
      first class mail, postage prepaid, or by telex or facsimile or by recognized
      overnight delivery service, addressed to the Holder at the address of the Holder
      as shown on the books of the Company, (i) at least 10 days’ prior written notice
      of the date on which the books of the Company shall close or a record shall
      be
      taken for such dividend, distribution or subscription rights or for determining
      rights to vote in respect of any such reorganization, reclassification,
      consolidation, merger, sale, dissolution, liquidation or winding up and (ii)
      in
      the case of any such reorganization, reclassification, consolidation, merger,
      sale, dissolution, liquidation or winding up, at least 10 days’ prior written
      notice of the date when the same shall take place. Such notice in accordance
      with the foregoing clause (i) shall also specify, in the case of any such
      dividend, distribution or subscription rights, the date on which the holders
      of
      Equity shall be entitled thereto and (ii) shall also specify the date on which
      the holders of Equity shall be entitled to exchange their Equity for securities
      or other property deliverable upon such reorganization, reclassification,
      consolidation, merger, sale, dissolution, liquidation or winding up, as the
      case
      may be.

    

    
      
        
        

      

      
        2

        
          

        

      

      
        
        

      

    

     

    4.    Event
      of Default.
      Each
      of
      the following shall constitute an “Event
      of Default”:

    

    (a)    the
      Company shall default in the payment of principal or interest on this Note
      and
      same shall continue for a period of five (5) days; or

    

    (b)    any
      of
      the representations or warranties made by the Company herein, in the Purchase
      Agreement, or in any agreement, certificate or financial or other written
      statements heretofore or hereafter furnished by the Company in connection with
      the execution and delivery of this Note or the Purchase Agreement, shall be
      false or misleading in any material respect at the time made, and such default
      is not cured within 14 days of receipt of written notice specifying the nature
      of the misrepresentation; or

    

    (c)    a
      breach
      of any covenant or agreement contained herein, in the Purchase Agreement, or
      in
      any agreement, certificate or instrument furnished by the Company in connection
      with the execution and delivery of this Note or the Purchase Agreement or in
      connection with the debt evidenced by this Note. 

    

    (d)    the
      Company shall (i) make an assignment for the benefit of creditors or commence
      proceedings for its dissolution; or (ii) apply for or consent to the appointment
      of a trustee, liquidator or receiver for its or for a substantial part of its
      property or business; or

    

    (e)    a
      trustee, liquidator or receiver shall be appointed for the Company or for a
      substantial part of its property or business without its consent and shall
      not
      be discharged within sixty (60) days after such appointment; or

    

    (f)    any
      governmental agency or any court of competent jurisdiction at the instance
      of
      any governmental agency shall assume custody or control of the whole or any
      substantial portion of the properties or assets of the Company and shall not
      be
      dismissed within sixty (60) days thereafter; or

    

    (g)    any
      final
      money judgment, writ or warrant of attachment, or similar process in excess
      of
      Two Hundred Thousand ($200,000) Dollars in the aggregate shall be entered or
      filed against the Company or any of its properties or other assets and shall
      remain unpaid, unvacated, unbonded or unstayed for a period of sixty (60) days
      or in any event later than five (5) days prior to the date of any proposed
      sale
      thereunder; or

    

    
      
        
        

      

      
        3

        
          

        

      

      
        
        

      

    

     

    (h)    bankruptcy,
      reorganization, insolvency or liquidation proceedings or other proceedings
      for
      relief under any bankruptcy law or any law for the relief of debtors shall
      be
      instituted by or against the Company and, if instituted against the Company,
      shall not be dismissed within sixty (60) days after such institution or the
      Company shall by any action or answer approve of, consent to, or acquiesce
      in
      any such proceedings or admit the material allegations of, or default in
      answering, a petition filed in any such proceeding. 

     

    5.    Acceleration
      and Remedies

    

    (a)   Acceleration
      of Maturity.
      If any
      Event of Default shall have occurred and be continuing, the Holder or Holders
      of
      at least 50.1% in aggregate principal amount of outstanding Notes may, by notice
      to the Company, declare the entire outstanding principal balance of the Notes,
      and all accrued and unpaid interest the thereon, to be due and payable
      immediately, and upon any such declaration the entire outstanding principal
      balance of the Notes, if any, and said accrued and unpaid interest shall become
      and be immediately due and payable, without presentment, demand, protest or
      other notice whatsoever, all of which are hereby expressly waived, anything
      in
      the Notes or in the Purchase Agreement to the contrary notwithstanding;
provided
      that if
      an Event of Default under paragraph (d) or (g) of Section 5 with respect to
      the
      Company or any Subsidiary shall have occurred, the outstanding principal amount
      of all of the Notes, and all accrued and unpaid interest thereon, shall
      immediately become due and payable in cash, without any declaration and without
      presentment, demand, protest or other notice whatsoever, all of which are hereby
      expressly waived, anything in the Notes or the Purchase Agreement to the
      contrary notwithstanding.

     

    (b)   Other
      Remedies.
      If any
      Event of Default shall have occurred and be continuing, from and including
      the
      date of such Event of Default to but not including the date such Event of
      Default is cured or waived, interest will accrue at an annual default rate
      of
      16% and, any Holder of 25% in aggregate principal amount of outstanding Notes
      may enforce its rights by suit in equity, by action at law, or by any other
      appropriate proceedings, whether for the specific performance (to the extent
      permitted by law) of any covenant or agreement contained in the Purchase
      Agreement or the Notes or in aid of the exercise of any power granted this
      Agreement or the Notes, and any Holder may enforce the payment of any Note
      held
      by such Holder and any of its other legal or equitable rights.

    

    (c)    Conduct
      No Waiver; Collection Expenses.
      No
      course of dealing on the part of any Holder, nor any delay or failure on the
      part of any Holder to exercise any of its rights, shall operate as a waiver
      of
      such right or otherwise prejudice such Holders rights, powers and remedies.
      If
      the Company fails to pay, when due, the principal or the premium, if any, or
      the
      interest on any Note, the Company will pay to each Holder, to the extent
      permitted by law, on demand, all costs and expenses incurred by such Holder
      in
      the collection of any amount due in respect of any Note hereunder, including
      reasonable legal fees incurred by such Holder in enforcing its rights
      hereunder.

    

    (d)   Annulment
      of Acceleration.
      If a
      declaration is made in accordance with paragraph 6(a), then and in every such
      case, the Holder or Holders of at least 50.1% in aggregate principal amount
      of
      outstanding Notes may, by an instrument delivered to the Company, annul such
      declaration and the consequences thereof, provided
      that at
      the time such declaration is annulled:

     

    
      
        
        

      

      
        4

        
          

        

      

      
        
        

      

    

     

    (i)    no
      judgment or decree has been entered for the payment of any monies due on the
      Notes or pursuant to the Purchase Agreement;

     

    (ii)   all
      arrears of interest on the Notes and all other sums payable on the Notes and
      pursuant to this Agreement (except any principal of or interest or premium
      on
      the Notes which has become due and payable by reason of such declaration) shall
      have been duly paid; and

     

    (iii)          every
      other Event of Default shall have been duly waived or otherwise made good or
      cured;

     

    provided, however,
      that
      only the Holder of the Note or Notes making the declaration permitted by the
      of
      paragraph 6(b) may annul such declaration; and provided, further,
      that no
      such annulment shall extend to or affect any subsequent Event of Default or
      impair any right consequent thereon.

    

    (e)    Remedies
      Cumulative.
      No
      right or remedy conferred upon or reserved to the Holders of Notes is intended
      to be exclusive of any other right or remedy, and every right and remedy shall
      be cumulative and in addition to every other right and remedy given hereunder
      or
      now and hereafter existing under applicable law. Every right and remedy given
      by
      the Purchase Agreement or by applicable law to the Holders of Notes may be
      exercised from time to time and as often as may be deemed expedient by the
      Holders. 

    

    6.    No
      Recourse to Stockholders, etc.
      No
      recourse shall be had for the payment of the principal of, or the interest
      on,
      this Note, or for any claim based hereon, or otherwise in respect hereof,
      against any incorporator, shareholder, employee, officer or director, as such,
      past, present or future, of the Company or any successor corporation, whether
      by
      virtue of any statute or rule of law, or by the enforcement of any assessment
      or
      penalty or otherwise, all such liability being, by the acceptance hereof and
      as
      part of the consideration for the issue hereof, expressly waived and
      released.

     

    7.    No
      Rights as Stockholder.
      No
      provision of this Note shall be construed as conferring upon the Holder the
      right to vote or to receive dividends or to consent or receive notice as a
      stockholder in respect of any meeting of stockholders or any rights whatsoever
      as a stockholder of the Company, unless and to the extent converted in
      accordance with the terms hereof.

    

    8.    Definitions.
      As used
      in this Note, 

    

    (a)    “Affiliate”
and
      “Associate”
shall
      have the respective meanings ascribed to such terms in Rule 12b-2 of the General
      Rules and Regulations under the Exchange Act. 

    

    (b)    “Beneficially
      Owned”
with
      respect to any securities shall mean having “beneficial ownership” of such
      securities (as determined pursuant to Rule 13d-3 under the Exchange Act),
      including pursuant to any agreement, arrangement or understanding, whether
      or
      not in writing.

     

    
      
        
        

      

      
        5

        
          

        

      

      
        
        

      

    

     

    (c)         
      “Original
      Issuance”
      means
      the Closing Date as set forth in the Purchase Agreement.

    

    (d)         
      “Purchase
      Agreement”
      shall
      mean the several agreements under which the Holders of the Notes have purchased
      the Notes from the Company.

    

    9.    Loss,
      Theft, Destruction of Note.
      Upon
      receipt of evidence satisfactory to the Company of the loss, theft, destruction
      or mutilation of this Note and, in the case of any such loss, theft or
      destruction, upon receipt of indemnity reasonably satisfactory to the Company
      (which shall not include the posting of any bond), or, in the case of any such
      mutilation, upon surrender and cancellation of this Note, the Company shall
      make, issue and deliver, in lieu of such lost, stolen, destroyed or mutilated
      Note, one or more new Notes of like tenor. This Note shall be held and owned
      upon the express condition that the provisions of this Section 12 are exclusive
      with respect to the replacement of mutilated, destroyed, lost or stolen Notes
      and shall preclude any and all other rights and remedies notwithstanding any
      law
      or statute existing or hereafter enacted to the contrary with respect to the
      replacement of negotiable instruments or other securities without the surrender
      thereof.

    

    10.    Record
      Owner.
      The
      Company may deem the person in whose name this Note shall be registered upon
      the
      registry books of the Company to be, and may treat such person as, the absolute
      owner of this Note for the purpose of conversion of this Note and for all other
      purposes, and the Company shall not be affected by any notice to the contrary.
      All such payments and such conversion shall be valid and effective to satisfy
      and discharge the liability upon this Note to the extent of the sum or sums
      so
      paid or the conversion so made.

     

    11.    Construction.
      This
      Note shall be deemed to be jointly drafted by the Company and the initial
      Holders of the Notes and shall not be construed against any person as the
      drafter hereof.

    

    12.    Amendments.
      The
      terms of the outstanding Notes may be amended as to the Holder and its
      respective successors and assigns, and the Company may take any action herein
      prohibited, or omit to perform any act required to be performed by it, if the
      Company shall obtain the written consent of the registered holders of not less
      than a majority of the outstanding principal amount of the Notes. This Agreement
      may not be waived, changed, modified, or discharged orally, but only by an
      agreement in writing signed by the party or parties against whom enforcement
      of
      any waiver, change, modification or discharge is sought or by parties with
      the
      right to consent to such waiver, change, modification or discharge on behalf
      of
      such party.

    

    13.    Failure
      or Indulgence Not Waiver.
      No
      failure or delay on the part of the Holder of this Note in the exercise of
      any
      power, right or privilege hereunder shall operate as a waiver thereof (except
      to
      the extent that such power, right or privilege must, in accordance with the
      terms of this Note, be exercised within a specified period of time and such
      period of time has lapsed without such power, right or privilege being
      exercised), nor shall any single or partial exercise of any such power, right
      or
      privilege preclude other or further exercise thereof or of any other right,
      power or privilege.

     

    
      
        
        

      

      
        6

        
          

        

      

      
        
        

      

    

     

    14.    Governing
      Law; Consent to Jurisdiction.
      This
      Note
      shall be governed by and construed in accordance with the laws of the State
      of
      New York. Each of the parties consents to the jurisdiction of the United States
      District Court for the Southern District of New York or the state courts of
      the
      State of New York located in New York County, New York in connection with any
      dispute arising under this Agreement and hereby waives, to the maximum extent
      permitted by law, any objection, including any objection based on forum non
      conveniens, to the bringing of any such proceeding in such
      jurisdictions.

    

    15.    Waiver
      of Jury Trial.
      EACH
      PARTY HERETO HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW,
      ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY
      OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS WARRANT. EACH
      PARTY HERETO (1) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY
      OF
      THE OTHER PARTIES HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT ANY OF THE
      OTHER
      PARTIES WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING
      WAIVER AND (2) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN
      INDUCED TO ENTER INTO THIS AGREEMENT, BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS
      AND CERTIFICATIONS IN THIS SECTION 15.

    

    
      
        
        

      

      
        7

        
          

        

      

      
        
        

      

    

    

    IN
      WITNESS WHEREOF, the Company has caused this instrument to be duly executed
      by
      an officer thereunto duly authorized.

     

    
      	 	 	 
	Dated:
              September ____, 2006  	BioMetrx,
              INC.
	 
 	 
 	 
 
	 	By:  	 
	
               

            	
              
Name:
              Mark Basile
              Title:
                Chief Executive Officer  

            
	 	 

    

     

    
      
        
        

      

      
        8THESE
      SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
      AMENDED, OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE SOLD OR OFFERED
      FOR
      SALE IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES
      OR
      AN OPINION OF COUNSEL OR OTHER EVIDENCE ACCEPTABLE TO THE COMPANY THAT SUCH
      REGISTRATION IS NOT REQUIRED.

    

    EXCHANGE
      AGREEMENT

    

    THIS
      EXCHANGE AGREEMENT, dated as of September __, 2006, is
      made
      by and between BioMetrx, Inc., a Delaware corporation (“Company”), and each
      purchaser identified on the signature pages hereto (each, including its
      successors and assigns, a “Purchaser”
and
      collectively the “Purchasers”).

    

    WHEREAS,
      on March 22, 2006 the Company issued to the Purchasers 12%
      Negotiable Promissory Notes in the aggregate principal amount of $100,000 (“12%
      Note”); and

    

    WHEREAS,
      the Notes were amended on July 19, 2006 to extend the maturity date from June
      21, 2006 to September 21, 2006; and

    

    WHEREAS,
      the Company and the Purchasers wish to provide for the terms and conditions
      pursuant to which the 12% Note may be exchanged for the Company’s 10% Note
      (“10%
      Note”),
      and
      attendant shares of Common Stock and Warrants as more fully described in
      Securities Purchase Agreement being executed simultaneously herewith of the
      Company;

     

    NOW,
      THEREFORE, for good and valuable consideration, the receipt and sufficiency
      of which the parties hereby acknowledge, the parties agree as
      follows:

    

    1.    Exchange
      of 12% Notes for 10% Notes.
      The
      Company and the Purchaser
      hereby agree that the 12% Notes shall be exchanged for the 10% Notes which
      are
      along with the shares of Common Stock and Warrants more fully described in
      the
      Securities Purchase Agreement.

    

    2.    Closing.
      At the
      Closing, the Purchaser shall deliver the original 12% Notes to the Company
      and
      the Company shall deliver the 10% Notes in the principal amount of $100,000,
      40,000 Shares of the Company Common Stock $.0001 par value (“Common Stock”) and
      100,000 Warrants (“Warrants”) to purchase Shares of the Common Stock to the
      Purchasers.

    

    3.    Further
      Assurances.
      In
      connection with the exchange of the 12% Notes, the Purchaser, by entering into
      this Exchange Agreement, agree to execute all agreements and other documents
      as
      reasonably requested by the Company.

     

    4.     Company
      Representations and Warranties and Covenants.
      The
      Company represents,
      warrants and covenants to the Purchaser as follows:

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    a.
      Organization.
      The
      Company is a corporation duly organized, validly existing and in good standing
      under the laws of Delaware and has all requisite corporate power and authority
      to own its properties and carry on its business as now being conducted.

    

    b.
      Authority;
      Enforceability.
      The
      Company has the requisite corporate power and authority to execute and deliver
      this Agreement and to carry out its obligations hereunder. The execution,
      delivery and performance of this Agreement and the consummation of the
      transactions contemplated hereby have been duly authorized by all necessary
      corporate action on the part of the Company and no other corporate proceedings
      on the part of the Company are necessary to authorize this Agreement or to
      consummate the transactions so contemplated. This Agreement has been duly
      executed and delivered by the Company and constitutes a valid and binding
      obligation of the Company, enforceable against the Company in accordance with
      its terms, except as (a) enforceability may be limited by applicable bankruptcy,
      insolvency, fraudulent transfer, moratorium or similar laws from time to time
      in
      effect affecting creditors’ rights generally and (b) the availability of
      equitable remedies may be limited by equitable principles of general
      applicability.

    

    c.
      Third
      Party Consents.
      No
      consent, authorization, order or approval of, or filing or registration with,
      any governmental authority or other person is required for the execution and
      delivery of this Agreement or the consummation by the Company of any of the
      transactions contemplated hereby.

    

    d.
      Common
      Stock.
      All
      shares of the Company’s Common Stock to be issued pursuant to this Agreement
      will be, when issued, free from liens, duly authorized, validly issued, fully
      paid and non-assessable.

    

    e.
      No
      Other Representations or Warranties.
      Except
      as set forth above in this Section 4, no other representations or warranties,
      express or implied, are made in this Agreement by the Company to the
      Purchaser.

    

    5.    Purchaser
      Representations and Warranties and Covenants.
      The
      Purchaser represents,
      warrants and covenants to the Company as follows:

    

    a.
      Investment
      Representation.
      Purchaser acknowledges
      that the 10% Notes, Common Stock and Warrants are restricted securities, that
      Purchaser
      is
      acquiring the Securities for its own account with the present intention of
      holding the Securities for purposes of investment and not with a view to
      distribution within the meaning of the Securities Act of 1933, as amended and
      that the Securities will bear a legend to such effect. Purchaser has relied
      solely on its independent investigation in making the decision to purchase
      the
      Debentures.

    

    b.
      No
      Other Representations or Warranties.
      Except
      as set forth above in this Section 5, no other representations or warranties
      of
      any kind, express or implied, are made in this Agreement by Purchaser to the
      Company.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    6.    Miscellaneous.

    

    a.
      Survival
      of Representations, Warranties and Agreements.
      The
      representations, warranties, covenants and agreements in this Agreement or
      in
      any instrument delivered pursuant to this Agreement shall survive the Closing
      and shall not be limited or affected by any investigation by or on behalf of
      any
      party hereto.

     

    b.
      Further
      Assurances.
      Each of
      the Company and Purchaser will use its, as the case may be, best reasonable
      efforts to take all action and to do all things necessary, proper or advisable
      on order to consummate and make effective the transactions contemplated by
      this
      Agreement.

     

    c.
      Entire
      Agreement; No Third Party Beneficiaries.
      This
      Agreement (including the documents, exhibits and instruments referred to herein)
      (a) constitutes the entire agreement and supersedes all prior agreements, and
      understandings and communications, both written and oral, among the parties
      with
      respect to the subject matter hereof, and (b) is not intended to confer upon
      any
      person other than the parties hereto any rights or remedies
      hereunder.

     

    d.
      Governing
      Law.
      This
      Agreement shall be governed and construed in accordance with the laws of the
      State of New York without regard to any applicable principles of conflicts
      of
      law.

     

    e.
      Counterparts.
      This
      Agreement may be executed in multiple counterparts, each of which shall be
      deemed an original and all of which taken together shall constitute one and
      the
      same document.

     

    f.
      Amendment
      and Modification.
      This
      Agreement may not be amended or modified except by an instrument in writing
      signed by each of the parties hereto.

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    IN WITNESS
      WHEREOF, the parties have caused this Agreement to be duly executed
      by their respective officers thereunto duly authorized as of the day and year
      first above written.

     

    
 

    BIOMETRX,
      INC.

    

    

    By:_____________________________

     

    

    

    By:______________________________

    Name:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00110-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00110-of-00352.parquet"}]]